Annovis Bio Inc (ANVS)

Jun 06, 2025

Annovis Bio to Host Webcast on June 24, 2025, Featuring Updates on Phase 3 AD Trial and PD Program Development - MyChesCo

Jun 06, 2025

Jun 06, 2025

Annovis Bio Inc. to Host Webcast on Alzheimer’s and Parkinson’s Programs Updates - citybuzz -

Jun 06, 2025

Jun 05, 2025

Annovis to Host Webinar and Live Q&A on June 24, 2025 - GlobeNewswire

Jun 05, 2025

Jun 05, 2025

Annovis Bio, Inc. to Host Live Webcast on Neurodegenerative Disease Developments and Phase 3 Trial Updates - Nasdaq

Jun 05, 2025

Jun 05, 2025

Annovis CEO Reveals Latest Alzheimer's Phase 3 Data and FDA Feedback on Parkinson's Program - Stock Titan

Jun 05, 2025

Jun 04, 2025

Annovis Bio (ANVS) Stock Surges Over 28% | ANVS Stock News - GuruFocus

Jun 04, 2025

Jun 04, 2025

Northern Trust Corp Acquires 10,846 Shares of Annovis Bio, Inc. (NYSE:ANVS) - Defense World

Jun 04, 2025

Jun 02, 2025

Annovis Bio, Inc. (NYSE:ANVS) Shares Purchased by Jane Street Group LLC - Defense World

Jun 02, 2025

May 28, 2025

INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Securities Class Action Lawsuit Has Been Filed on Behalf of Annovis Bio, Inc. (ANVS) Investors and Encourages Investors to Contact the Firm Before October 18, 2021 - The Globe and Mail

May 28, 2025

May 26, 2025

Down Syndrome Market: Epidemiology, Therapies, Companies, - openPR.com

May 26, 2025

May 20, 2025

Annovis Bio to Host Patient-Centered Webcast on Key Clinical Developments - MSN

May 20, 2025

May 20, 2025

Annovis Bio Advances Phase 3 Alzheimer’s Trial Amid Steady Financial Progress - MSN

May 20, 2025

May 17, 2025

Canaccord Genuity Group Issues Pessimistic Forecast for Annovis Bio (NYSE:ANVS) Stock Price - Defense World

May 17, 2025

May 16, 2025

Annovis Bio, Inc. (NYSE:ANVS) Given Average Recommendation of “Buy” by Brokerages - Defense World

May 16, 2025

May 15, 2025

Annovis Bio (ANVS) Target Price Lowered as Phase 3 Alzheimer's T - GuruFocus

May 15, 2025

May 15, 2025

Canaccord cuts Annovis Bio stock target to $17; keeps Buy rating - Investing.com Australia

May 15, 2025

May 15, 2025

Levi Strauss To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga

May 15, 2025

May 15, 2025

Annovis Bio (ANVS) Price Target Reduced by Canaccord Genuity | ANVS Stock News - GuruFocus

May 15, 2025

May 15, 2025

Annovis Bio Launches Phase 3 Alzheimer’s Trial, Expands Research Efforts - citybuzz -

May 15, 2025

May 13, 2025

Annovis Bio Appoints New Principal Financial Officer - TipRanks

May 13, 2025

May 13, 2025

Annovis Provides Corporate Updates And Reports First Quarter 2025 Financial Results - marketscreener.com

May 13, 2025

May 13, 2025

Annovis Bio Inc. Provides Corporate Updates and Q1 2025 Financial Results, Initiates Pivotal Phase 3 Clinical Trial for Alzheimer’s Disease - Nasdaq

May 13, 2025

May 13, 2025

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results - GlobeNewswire

May 13, 2025

May 13, 2025

Annovis Bio's New Phase 3 Alzheimer's Drug Trial Targets Both Symptoms and Disease Modification - Stock Titan

May 13, 2025

May 10, 2025

Annovis Bio (ANVS) Projected to Post Quarterly Earnings on Monday - Defense World

May 10, 2025

May 06, 2025

Annovis Bio Appoints Hui Liu as Director of Biostatistics - MSN

May 06, 2025

Apr 30, 2025

Annovis Bio Strengthens Research Team with Appointment of Hui Liu as Director of Biostatistics - citybuzz -

Apr 30, 2025

Apr 29, 2025

Annovis Bio hires new director of biostatistics amid AD trial - Investing.com

Apr 29, 2025

Apr 29, 2025

Annovis Bio Appoints Hui Liu As Director Of Biostatistics - marketscreener.com

Apr 29, 2025

Apr 29, 2025

Annovis Bio Bolsters Alzheimer's Phase 3 Trial Team: Statistics Expert Joins at Critical Stage - Stock Titan

Apr 29, 2025

Apr 26, 2025

LAWSUITS FILED AGAINST SLQT, ANVS and VIEWJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire

Apr 26, 2025

Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025

Apr 21, 2025

Annovis Bio, Inc. (NYSE:ANVS) Receives Average Recommendation of “Buy” from Analysts - Defense World

Apr 21, 2025

Apr 15, 2025

Head-To-Head Survey: Eterna Therapeutics (NASDAQ:ERNA) and Annovis Bio (NYSE:ANVS) - Defense World

Apr 15, 2025

Apr 09, 2025

Annovis Bio stock plunges to 52-week low of $1.14 By Investing.com - Investing.com Canada

Apr 09, 2025

Apr 09, 2025

Annovis Bio stock plunges to 52-week low of $1.14 - Investing.com

Apr 09, 2025

Apr 09, 2025

Buntanetap shows early potential for Parkinson’s-related dementia - The Pharma Letter

Apr 09, 2025

Apr 08, 2025

Parkinson's Disease Pipeline Analysis and Clinical Trials - openPR.com

Apr 08, 2025

Apr 03, 2025

Buntanetap for Parkinson’s disease - Parkinson's News Today

Apr 03, 2025

Apr 02, 2025

Annovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development Summit - MSN

Apr 02, 2025

Mar 31, 2025

Annovis Bio stock hits 52-week low at $1.52 amid sharp decline By Investing.com - Investing.com South Africa

Mar 31, 2025

Mar 31, 2025

Annovis Bio stock hits 52-week low at $1.52 amid sharp decline - Investing.com India

Mar 31, 2025

Mar 31, 2025

Annovis Bio Receives Non-Compliance Notice from NYSE - MSN

Mar 31, 2025